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Abstract
Background: In daily clinical setting, some patients affected by relapsing-remitting Multiple Sclerosis (RRMS) are
switched from the low-dose to the high-dose Interferon beta (IFNB) in order to achieve a better control of the
disease.
Purpose: In this observational, post-marketing study we reported the 2-year clinical outcomes of patients switched
to the high-dose IFNB; we also evaluated whether different criteria adopted to switch patients had an influence on
the clinical outcomes.
Methods: Patients affected by RRMS and switched from the low-dose to the high-dose IFNB due to the
occurrence of relapses, or contrast-enhancing lesions (CELs) as detected by yearly scheduled MRI scans, were
followed for two years. Expanded Disability Status Scale (EDSS) scores, as well as clinical relapses, were evaluated
during the follow-up period.
Results: We identified 121 patients switched to the high-dose IFNB. One hundred patients increased the IFNB dose
because of the occurrence of one or more relapses, and 21 because of the presence of one or more CELs, even in
absence of clinical relapses. At the end of the 2-year follow-up, 72 (59.5%) patients had a relapse, and 51 (42.1%)
reached a sustained progression on EDSS score. Overall, 85 (70.3%) patients showed some clinical disease activity (i.
e. relapses or disability progression) after the switch.
Relapse risk after increasing the IFNB dose was greater in patients who switched because of relapses than those
switched only for MRI activity (HR: 5.55, p = 0.001). A high EDSS score (HR: 1.77, p < 0.001) and the combination of
clinical and MRI activity at switch raised the risk of sustained disability progression after increasing the IFNB dose
(HR: 2.14, p = 0.01).
Conclusion: In the majority of MS patients, switching from the low-dose to the high-dose IFNB did not reduce the
risk of further relapses or increased disability in the 2-year follow period.
Although we observed that patients who switched only on the basis on MRI activity (even in absence of clinical
attacks) had a lower risk of further relapses, larger studies are warranted before to recommend a switch algorithm
based on MRI findings.
Background
Three formulation of Interferon beta (IFNB) are nowa-
days approved as disease modifying agents for subjects
with relapsing-remitting (RR) Multiple Sclerosis (MS):
IFNB-1b 250 mcg subcutaneous every other day (s.c.,
e.o.d.) (Betaferon, Bayer Schering, Berlin, Germany);
IFNB-1a 30 mcg intramuscular once weekly (i.m., o.w.)
(Avonex, Biogen Idec, Cambridge, USA); IFNB-1a 22
or 44 mcg subcutaneous three times per week (s.c., t.p.
w.) (Rebif, Merck Serono, Geneva, Switzerland). Large
randomised trials demonstrated that IFNB reduces the
frequency of MS attacks and the number of new
lesions on magnetic resonance imaging (MRI) [1-6].
Also, post-marketing studies suggest a long-term bene-
fit of IFNB treatment on disease activity and disability
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patients experience a breakthrough disease, i.e. evidence of
clinical or imaging disease activity or progression despite
the IFNB treatment [11]. Therefore, a significant propor-
tion of subjects requires treatment switching or escalation
in order to avoid accumulation of irreversible disability.
To date, there is no evidence to guide an alternative
therapy in patients with breakthrough disease [11].
However, in daily clinical setting some patients starting
with the low-dose (i.m., o.w. 30 mcg, or s.c., t.p.w. 22
mcg IFNB-1a) are routinely switched to the high-dose
IFNB (s.c., e.o.d. 250 mcg IFNB-1b, or s.c., t.p.w. 44 mcg
IFNB-1a) in case of breakthrough disease, according to
suggestions coming from therapeutic recommendation
of consensus groups [12,13].
Two head-to-head studies comparing i.m. 30 mcg
IFNB-1a o.w. with s.c. 250 mcg IFNB-1b e.o.d. and 44
mcg IFNB-1a t.p.w. (INCOMIN and EVIDENCE, respec-
tively) provided evidences that naive patients started
with the high-dose IFNB had a better outcome than
those receiving a low dose regimen [14,15]. It has also
been suggested that increasing the IFNB dose may be
useful in reducing mean relapse rate and the accumula-
tion of subclinical lesions as detected on MRI [16,17].
However, these studies have not investigated whether
the criteria adopted to switch patients to the high-dose
IFNB could have an influence on the clinical outcomes.
The 2-year clinical outcomes of patients switched
from the low-dose to the high and/or more frequently
administered dose of IFNB are reported in the present
observational study. Moreover, we attempted to identify
which patients with breakthrough disease could benefit
from an increase of the IFNB dose.
Methods
Study design and participants
Patients affected by RRMS [18] according to Poser [19]
or McDonald Criteria [20], and switched to a more fre-
quently administered and/or higher dose of IFNB
(Betaferon or Rebif 44) in consequence of breakthrough
disease during the low-dose IFNB regimen (Avonex or
Rebif 22) were included in this 2-year, independent,
observational, post-marketing study at the MS Centre of
S. Andrea Hospital in Rome. There was no well-defined
protocol for switching patients to the high-dose IFNB
(occurrence of one or more relapses and/or MRI activ-
ity), but it was a decision taken by the neurologist
depending on the growing availability over years of new
drugs active against MS (i.e., Natalizumab, experimental
treatment, etc).
Patients were regularly followed-up from the start of
the IFNB treatment; clinical and MRI data were pro-
spectively collected and stored into an electronic data-
base (after obtaining an informed consent by each
patient). The local Ethical committee board provides
exemption of approval for post-marketing prospective
studies.
The study design with relative time-points are
d e s c r i b e di nF i g u r e1 .W ed e f i n e da s“switch” the time-
point at which patients interrupted the low-dose and
started the higher IFNB dose; therefore, we defined a
pre-switch period (i.e., the time frame elapsed between
the start of the IFNB treatment and the switch) and a 2-
year observational post-switch period.
Patients receiving a low-dose IFNB only for titration,
or those discontinuing the IFNB treatment mainly for
poor tolerance, or those with previous exposure to
immunomodulant or immunosuppressive agents were
excluded from this study.
Clinical data, including the occurrence of relapses and
the Expanded Disability Status Scale (EDSS) score [21],
were evaluated for each subject every 3 months.
Unscheduled visits were also performed in suspect of
relapse or any other clinically relevant condition.
An exacerbation was defined as the appearance or
reappearance of one or more symptoms attributable to
MS, accompanied by objective deterioration on neurolo-
gical examination lasting at least 24 hours, in the
Figure 1 Study design with relative time-points. Note that pre-IFNB and low IFNB dose periods had a different duration for each patient,
while after switch all patients were followed for 2 years.
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for at least 30 days [19,20].
We also collected yearly brain and spinal cord MRI
since the start of treatment with IFNB, focusing on the
absence/presence of MRI activity (i.e. the detection of at
least one contrast-enhancing lesions); additional MRI
scans were performed, if necessary. Clinical examination
(including EDSS score) and MRI scan were done in
stable patients (i.e. at least 30 days after the last assump-
tion of steroids administered for relapses).
Outcome measures
We considered two main outcomes over the 2-year
observation period: (a) the occurrence of at least one
relapse, and (b) a sustained progression of 1 or more
points on EDSS score (starting after the switch and con-
firmed in two consecutive neurological visits separated
by at least a 6-month interval).
Statistical analysis
All values are expressed as a mean ± standard deviation
(± SD) or median (range), as appropriate. Differences
between groups were tested by using the Chi-square test
and the U Mann-Whitney test.
Two Cox proportional hazards models were built for
identifying the predictors of experiencing a relapse or a
sustained progression on EDSS score after the switch.
As main time variable for time-to-event analyses we
considered the interval (in years) elapsed between the
switch and last visit, or high IFNB dose discontinuation,
or outcome reach, whichever came first.
Gender, age, MS duration, EDSS score, presence/
absence of an active MRI (each considered at the time
of switch), pre-IFNB annualised relapse rate, IFNB type
(Betaferon or Rebif 44), as well as duration of initial
IFNB treatment, number of relapses, and EDSS change
occurred during the low-dose IFNB regimen were
included as covariates in each model. Variables were
added in the models in a forward stepwise fashion, and
interactions terms were tested, where appropriate. All
models were stratified by IFNB type received by patients
before the switch (Avonex or Rebif 22).
Data have been analysed by using the Statistical Pack-
age for Social Sciences, version 16.0 (SPSS, Chicago, IL,
USA).
Results
Participants
We examined 283 patients starting the low-dose IFNB
formulation from October 1997 to March 2008 (Avonex,
n = 120; Rebif 22, n = 163). Mean (SD) duration of
IFNB treatment was 4.3 (2.3) years, and mean annual-
ised relapse rate was 0.48 (range 0-3). A total of 108
(38.1%) patients had a sustained EDSS increase during
IFNB treatment.
Out of these 283 patients, 121 patients switched to the
high-dose IFNB, while 162 continued to receive the low-
dose IFNB. Table 1 shows the demographic and clinical
characteristics of patients who switched to the high-
dose IFNB and those who did not. At the start of treat-
ment with IFNB there were no differences between the
two groups.
Among the 121 patients who increased the IFNB dose,
therapy switching included: Rebif 22®Rebif 44 (n = 59,
47.9%), Avonex®Rebif 44 (n = 46, 38.4%), Avonex®Be-
taferon (n = 16, 13.7%). After the switch to the high-
dose IFNB, 72 (59.5%) patients experienced a relapse,
and 51 (42.1%) patients reached a sustained progression
on EDSS score. Overall, 85 (70.3%) patients showed
some clinical disease activity (i.e. relapse or disability
progression) over the 2-year observation period after the
switch.
Risk of relapses or worsening in disability after the switch
One hundred (82.6%) patients switched to the high-dose
IFNB due to MS attacks (40 also had an active MRI
scan at switch), while 21 (17.4%) patients switched due
to evidence of activity on MRI scan, but not relapses,
during the low-dose IFNB regimen.
Only 5 patients (23.8%) who were switched on the
basis of MRI activity experienced a further relapse,
while 67 (67.0%) of patients switching because of
relapses had a further exacerbation over the 2-year after
the increase of IFNB dose (p < 0.001).
Table 1 Demographic and clinical characteristics of 283 patients starting a low IFNB dose
Patients switching to high
IFNB dose n = 121
Patients remaining on low
IFNB dose n = 162
Pooled
n = 283
Male gender, n (%) 39 (32.2) 49 (30.2) 88 (31.1)
Age, years 31.5 (8.5) 32.8 (9.8) 32.2 (9.2)
MS duration, years 5.4 (5.3) 6.1 (5.9) 5.8 (5.7)
Annualised relapse rate pre-IFNB 1.00 (0.74) 0.92 (0.76) 0.95 (0.75)
EDSS score, median [range] 1.5 [0 - 3.5] 1.5 [0 - 3.5] 1.5 [0 - 3.5]
Active MRI scan, n (%) 65 (53.7) 69 (42.6) 134 (47.3)
All value are expressed as mean (standard deviation), unless indicated otherwise.
All p-values are > 0.05
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reaching a sustained progression on EDSS score were
observed between patients who increased the IFNB dose
because of relapses and those who switched only on the
basis of MRI (p = 0.08).
According to the Cox model, when compared with
patients switched only on the basis of MRI activity (i.e. no
relapses during the low-dose IFNB regimen), those relapsing
were more likely of having a further relapse even after the
switch (HR: 5.55, 95% C.I. 2.22 - 13.85, p = 0.001). More-
over, this risk of relapsing during the 2-year observational
period was related with a younger age at switch (HR: 0.94,
95% C.I. 0.91 - 0.97; p < 0.001), and the number of clinical
bouts occurred before the switch: one bout confers a risk
ratio of 3.56 (95% C.I. 1.34 - 8.42; p = 0.01), two or more
bouts a risk ratio of 7.89 (95% C.I. 3.10 - 19.85; p < 0.001)
(see Table 2). The risk of further relapses was not increased
in patients who switched to the high-dose IFNB because of
a combination of clinical and MRI activity at switch.
The variables predictive for reaching a sustained disabil-
ity progression after the switch were the EDSS score at
baseline (HR: 1.77, 95% C.I. 1.39 - 2.26; p < 0.001), and the
combination of clinical and radiological activity at switch
(HR: 2.14, 95% C.I. 1.16 - 3.96; p = 0.01) (see Table 3).
Discussion
Results from the present study suggest that the risk of
having a relapse despite the increase of IFNB dose raised
according to the number of clinical attacks occurred
during the assumption of the low-dose IFNB, and it is
reduced when the switching was based on MRI findings
rather than on clinical activity. Moreover, the chance of
being progression-free after the switch is related to a
lower EDSS score and the absence of clinical and MRI
activities. At this regard, we may assume that in some
patients an incomplete recovery from relapse occurred,
with a substantial influence on their EDSS scores.
Overall, less than 1/3 of our patients remained free
from clinical disease activity (i.e. absence of relapse and
sustained progression on EDSS score) over the 2-year
observational period follow i n gt h ei n c r e a s eo fI F N B
dose. This could imply that the majority of switchers
should be considered poor responder to IFNB therapy
regardless the dose and/or frequency of administration,
and further supports the hypothesis that a treatment
strategy encompassing the increase of IFNB dose should
be useful only in some selected cases.
After the increase of IFNB dose, the majority of
patients switched only for the evidence of MRI activity
had a better clinical outcome than those switched
because of the occurrence of relapses. Therefore, we
might suggest that monitoring the effect of IFNB treat-
ment with regular MRI scans is recommendable even in
absence of clinical relapses.
It has been known that conventional MRI represents a
powerful tool to monitor latent disease activity, providing
a measurable and sensible marker of response to IFNB
therapy [22-25]. However, we cannot exclude that
patients switched only on the basis of MRI findings
might also have had good outcomes without switching to
the high-dose IFNB, as the absence of a control group.
At this regard, Rio and colleagues showed that patients
with only MRI activity and no relapses in the first year of
IFNB treatment did not experience an increase of
relapses or disability over a 3-year follow-up [26].
Although randomized clinical trials demonstrated a
more pronounced effect of high-dose, high-frequency
IFNB when compared with both the low-dose, equal-fre-
quency [1,27] and the low-dose, low-frequency regimens
[14,15] in naïve patients, data on the effectiveness of
increasing the IFNB dose in patients with breakthrough
disease are scarce. The open-label extension phase of the
EVIDENCE study, involving 223 patients converted from
Avonex to Rebif 44, documented a 50% reduction in the
annualised relapse rate after the switch [16]. However,
we must consider also that in the EVIDENCE study all
patients originally randomized to Avonex were offered to
receive Rebif 44, independently from the response status
Table 2 Final model for the stepwise Cox hazard model
analysis showing Hazard Ratio (with relative confidence
intervals and p-values) for relapsing after the increase of
IFNB dose
HR 95% C.I. p-value
Male gender 0.68 0.39 - 1.16 0.1
Age at switch (each year) 0.94 0.91 - 0.97 <0.001
No. of relapses occurred
during the low-dose IFNB regimen
0 (*) Ref. - -
1 3.56 1.34 - 8.42 0.01
≥ 2 7.89 3.10 - 19.85 <0.001
IFNB type (Betaferon or Rebif 44) 1.14 0.52 - 2.51 0.7
IFNB: Interferon Beta; EDSS: Expanded Disability Status Scale.
(*) this value refers to patients switched only on the basis of an active MRI
scan.
Table 3 Final model for the stepwise Cox hazard model
analysis showing Hazard Ratio (with relative confidence
intervals and p-values) for worsening in disability after
the increase of IFNB dose
HR 95% C.I. p-value
Male gender 1.68 0.88 - 2.13 0.1
Age at switch (each year) 0.98 0.94 - 1-02 0.3
Interaction term (relapse *
active MRI scan at switch)
2.14 1.16 - 3.96 0.01
EDSS score at switch (each point) 1.77 1.39 - 2.26 < 0.001
IFNB type (Betaferon or Rebif 44) 0.83 0.28 - 2.85 0.7
IFNB: Interferon Beta; EDSS: Expanded Disability Status Scale.
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suggested that increasing the IFNB-1a dose and fre-
quency could rapidly reduce ongoing disease activity,
they cannot discharge the hypothesis that the significant
reduction in relapse rate might be due, at least in part, to
the regression to the mean phenomenon.
Some open-label studies exploring the usefulness of
switching among immunomodulating drugs had different
designs and provided conflicting results [28-30]. Two stu-
dies reported a decrease in both relapse rate and propor-
tion of relapse-free subjects after the switch [29,30], whilst
the QUASIMS study did not provide any support of more
favourable outcomes after switching from an IFNB formu-
lation to another [28]. One possible explanation of this
discrepancy is that these observational surveys considered
different subtype of switch (i.e. from IFNB-1a to IFNB-1b
and viceversa, from IFNB to GA, etc.); also, these studies
were not specifically aimed to determine the crude effect
of an increase of the IFNB dose. Furthermore, in some
studies the patients were switched on the basis of tolerabil-
ity rather than a persistent disease activity.
In the present study, patients had variable periods of
observation before and after the switch, thus precluding
any attempt to estimate the effectiveness of an increase
of the IFNB dose in suppressing disease activity and
slowing disability progression.
Being an observational report, our study suffers from
other limits, such as the small sample size, the unavail-
ability of control group, blindness and randomization, as
well as the lack of data on neutralising antibodies
(NAbs) against IFNB. However, there is evidence that
NAbs presence could explain only the 20% of the sub-
optimal response to IFNB treatment [31].
Despite these limits, our study might contribute to
define a therapeutic algorithm to manage breakthrough
disease in patients on treatment with a low-dose IFNB.
The identification of patients with subclinical disease
activity during the low-dose IFNB treatment, and an
early switch to the high-dose IFNB, seem to be effective
in achieving a better control of the disease. On the con-
trary, when relapses occurred during the pre-switch per-
iod, especially in combination with MRI activity,
patients did not seem benefit from the increase of the
IFNB dose in the following years.
Since efficacy of GA has been demonstrated compar-
able to IFNB [32-34], switching among immunomodu-
lating treatments may represent an interesting approach
in case of treatment failure [35,36]. The scientific ratio-
nale for switching to other therapies is strongest for
patients on IFNB therapy with persistent high-titre of
NAbs [37]. However, a more aggressive approach (Nata-
lizumab or Mitoxantrone) is warranted for patients at
high risk of accumulation of fixed disability or with
shorter intervals between attacks [13].
Conclusions
We suggest neurologists to consider the presence of sub-
clinical activity, as detected on MRI, in the decision to
switch a patient from the low-dose to the high-dose IFNB,
even in absence of clinical relapses. Further efforts are war-
ranted to clearly define whether MRI findings might be con-
sidered a key element in the choice of increase the IFNB
dose when the response to the low-dose IFNB is suboptimal.
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